Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab ± Ociperlimab in Previously Treated Recurrent or Metastatic Cervical Cancer
CTR20212809Phase 2Completed
- Sponsor
- BeiGene
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, ociperlimab in Cervical Cancer (CC), sponsored by BeiGene. Started Feb 2022; status: completed.
02
Drugs
tislelizumabociperlimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20212809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212809.